Jeffrey Poulton Sells 2,780 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Jeffrey Poulton sold 2,780 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the completion of the sale, the executive vice president owned 57,465 shares in the company, valued at approximately $20,852,324.55. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $359.18 on Friday. The company has a 50-day moving average price of $420.41 and a two-hundred day moving average price of $421.12. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The stock has a market cap of $47.45 billion, a price-to-earnings ratio of 1,496.56 and a beta of 0.32. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the company. Thematics Asset Management acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $1,995,000. Teacher Retirement System of Texas increased its holdings in shares of Alnylam Pharmaceuticals by 3.2% in the 2nd quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock valued at $11,872,000 after purchasing an additional 1,123 shares during the period. Generali Asset Management SPA SGR lifted its position in shares of Alnylam Pharmaceuticals by 6,368.0% in the third quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after purchasing an additional 3,184 shares in the last quarter. Investment Management Corp of Ontario boosted its holdings in shares of Alnylam Pharmaceuticals by 35.4% during the second quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock worth $10,279,000 after purchasing an additional 8,244 shares during the period. Finally, Congress Asset Management Co. purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at approximately $54,173,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Bank of America reduced their price target on Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating for the company in a research report on Monday. Barclays increased their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Morgan Stanley boosted their price objective on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research note on Monday, October 6th. JPMorgan Chase & Co. cut their target price on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research note on Monday, October 13th. Finally, Royal Bank Of Canada lifted their price target on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, September 19th. Twenty-two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $490.96.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Analysts maintain a generally constructive stance: ALNY carries a consensus “Moderate Buy” from sell‑side firms, supporting a bullish medium‑term view for the shares. Alnylam Pharmaceuticals, Inc. Receives Consensus Rating of “Moderate Buy” from Analysts
• Positive Sentiment: Needham published a bullish forecast, highlighting upside tied to Alnylam’s longer‑term (Alnylam 2030) growth plan — a catalyst that could support recovery if execution meets targets. Needham & Company LLC Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
• Neutral Sentiment: Context/valuation pieces are circulating that reassess ALNY’s premium valuation versus the newly unveiled Alnylam 2030 plan — useful for investors weighing long‑range upside against current multiples. A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
• Neutral Sentiment: Analyst opinions are mixed across the healthcare coverage universe, with some firms trimming targets while others remain upbeat — this divergence contributes to higher intraday volatility. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY) …
• Negative Sentiment: Concentrated insider selling: multiple senior executives — including CEO Yvonne Greenstreet and several EVPs — disclosed sizable share sales on Jan. 12–13 (individual sales in the $0.5M–$3.5M range), which typically increases near‑term sell pressure and raises investor caution. Alnylam Insiders Quietly Unload a Major Chunk of Stock in Synchronized Sell‑Off
• Negative Sentiment: Market reaction to the company’s ambitious 2026 guidance and the Alnylam 2030 plan was negative — coverage noted a sharp intraday slide after the announcement — and Bank of America issued a pessimistic forecast that may amplify selling pressure. Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal
• Negative Sentiment: Bank of America lowered its outlook and flagged downside risk, adding to analyst‑driven selling pressure following the company’s strategic/guidance update. Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.